# ORIC Pharmaceuticals, Inc. (ORIC)

> Source: Nexqual · https://nexqual.com/ORIC · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, ORIC Pharmaceuticals, Inc. (ORIC), nexqual.com/ORIC" · informational, not investment advice.

**Price:** USD 13.63 (-1.59% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 13.85 · day 13.38–14.14 · 52w 7.23–14.68 · market cap $1.41B · NMS

## Key facts
- 1 of 80 tracked superinvestors hold ORIC (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 7 Form 4 filings, $1.7M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 4 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.94 on a 1–5 scale) (16 analysts), mean target USD 21.64 (range 14–27).
- Total return with dividends: 1Y +9.7% vs S&P 500 +14.9%; 5Y -8.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-12, EPS estimate USD -0.38, revenue estimate $0K.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$78.9M | -$91.8M | -$111M | -$143M | -$143M | -$156M |
| Net income | -$78.7M | -$89.1M | -$101M | -$128M | -$129M | -$140M |
| EPS (diluted) | -$2.07 | -$2.25 | -$1.96 | -$1.83 | -$1.47 | — |
| Free cash flow | -$60.5M | -$77.2M | -$86.5M | -$114M | -$112M | -$112M |
| Cash + short-term investments | $237M | $206M | $208M | $256M | $281M | — |
| Total debt | $10.5M | — | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 3.7x · FCF yield -7.95% · Earnings yield -9.93%

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold ORIC. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.16% | $55.5M | Reduced -12.0% |

## Insider sales (SEC Form 4, open-market, last ~7 months)
7 of 7 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-20 | Piscitelli Dominic | Chief Financial Officer | 14,000 | $189K | 16.7% | Yes (adopted May 26, 2026) | Routine (sold in Dec each year 2023–2025; this trade is outside those months) |
| 2026-10-01 | Heyman Richard A. | Director | 6,700 | $87K | 2.7% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-09-28 | Piscitelli Dominic | Chief Financial Officer | 13,400 | $181K | 16.1% | Yes (adopted May 26, 2026) | Routine (sold in Dec each year 2023–2025; this trade is outside those months) |
| 2026-09-24 | Piscitelli Dominic | Chief Financial Officer | 600 | $8K | 0.9% | Yes (adopted May 26, 2026) | Routine (sold in Dec each year 2023–2025; this trade is outside those months) |
| 2026-08-26 | Piscitelli Dominic | Chief Financial Officer | 77,000 | $1.1M | 52.4% | Yes (adopted May 26, 2026) | Routine (sold in Dec each year 2023–2025; this trade is outside those months) |
| 2026-07-24 | Heyman Richard A. | Director | 13,100 | $157K | 5.1% | Yes | Too little history (no open-market trades in 2023–2025) |
| 2026-07-06 | Heyman Richard A. | Director | 300 | $4K | 0.1% | Yes | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 1.94 on a 1–5 scale), 16 analysts; mean target USD 21.64 (low 14, high 27).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | JP Morgan | Target raised | Overweight | $23 → $26 |
| 2026-10-05 | Leerink Partners | Initiated | Outperform | $26 |
| 2026-09-23 | BTIG | Initiated | Buy | $26 |
| 2026-08-10 | HC Wainwright & Co. | Target raised | Buy | $25 → $27 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +9.7% | -8.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +9.8% | -1.8% |
| Volatility (annualized) | 88.5% | 88.3% |
| Max drawdown | -46.1% (Mar 2026→Apr 2026) | -86.0% (Nov 2021→Oct 2022) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/ORIC · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Company outlook (8-K filed 2026-08-03)

- "The Himalayas-1 trial is expected to enroll approximately 600 patients from over 250 sites in 25 countries, randomized 1:1 to receive 400 mg once daily rinzimetostat (with or without food) in combination with darolutamide versus physician's choice of an androgen receptor (AR) inhibitor or docetaxel."
- "The company expects its cash and investments to fund the operating plan into 2H 2028. • R&D Expenses: Research and development (R&D) expenses were $36.3 million for the three months ended June 30, 2026, compared to $30.5 million for the three months ended June 30, 2025, an increase of $5.7 million."
- "These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.38 | $-0.37 | +1.9% | $0 | 13 |
| Next quarter (ends 2026-12-31) | $-0.40 | $-0.39 | +1.6% | $0 | 13 |
| Current fiscal year (ends 2026-12-31) | $-1.49 | $-1.47 | +1.5% | $0 | 13 |
| Next fiscal year (ends 2027-12-31) | $-1.67 | $-1.61 | +3.6% | $0 | 13 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-12): ±38.8%; last 8 reports averaged ±8.7%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 174.9% | ±38.8% |
| 2026-12-18 | 56 | 165.4% | ±50.9% |
| 2027-01-15 | 84 | 175.2% | ±65.0% |
| 2027-02-19 | 119 | 163.9% | ±71.5% |
| 2027-05-21 | 210 | 145.3% | ±82.3% |